<DOC>
	<DOCNO>NCT00006241</DOCNO>
	<brief_summary>RATIONALE : Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy radiation therapy . Treating peripheral stem cell laboratory remove exist cancer cell may improve effectiveness transplant . PURPOSE : Randomized phase II trial compare effectiveness treat peripheral stem cell untreated stem cell patient relapse low- intermediate-grade non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Peripheral Stem Cell Transplantation Treating Patients With Relapsed Low- Intermediate-Grade Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine effectiveness B-cell high density microparticles ( BCell-HDM ) device purge B-cells peripheral blood stem cell ( PBSC ) harvest patient relapse low intermediate grade B-cell non-Hodgkin 's lymphoma . II . Determine recovery T-cells CD34+ cell BCell-HDM process PBSC patient . III . Compare hematopoietic engraftment follow infusion autologous PBSC purge use BCell-HDM device versus unpurged autologous PBSC patient receive high dose chemotherapy . IV . Determine toxicity regimen patient . V. Determine occurrence adverse effect regimen patient . OUTLINE : This randomize , double blind , multicenter study . Patients stratify grade lymphoma ( low v intermediate ) , type myeloablative conditioning regimen ( chemotherapy v chemotherapy/total body irradiation ) , center . Patients randomize one two treatment arm . Patients undergo peripheral blood stem cell ( PBSC ) harvest 4 consecutive day . A myeloablative conditioning regimen either chemotherapy alone chemotherapy/total body irradiation give within 4 week PBSC harvest . Prior randomization one patient center receive PBSC transplantation use cell purge B-cell high density microparticle ( BCell-HDM ) device . Arm I : Patients receive BCell-HDM treat PBSC transplantation day 0 . Arm II : Patients receive untreated PBSC transplantation day 0 . Patients receive filgrastim ( G-CSF ) subcutaneously begin day 1 continue blood count recover . Patients follow day 30 100 , 6 12 month . PROJECTED ACCRUAL : A total 115 patient ( 15 prerandomization study , 50 treatment arm ) accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis relapse low intermediate grade Bcell nonHodgkin 's lymphoma CD20+ CD19+ tumor cell Bone marrow involvement le 20 % intratrabecular space All tumor mass less 5 cm dimension In second great remission either complete remission minimal disease state OR Failed achieve remission primary induction therapy , achieve minimal disease additional chemotherapy radiotherapy OR Persistent splenomegaly otherwise minimal disease No active CNS involvement A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 65 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL Renal : Creatinine great 2.0 mg/dL Cardiovascular : LVEF least 45 % Pulmonary : DLCO least 50 % predict Other : Not pregnant Negative pregnancy test No prior malignancy except carcinoma situ cervix basal cell carcinoma skin No known hypersensitivity nickel No known hypersensitivity mouse proteins HIV negative HTLV I II negative PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 month since prior unconjugated antiBcell monoclonal antibody ( mAb ) ( e.g. , rituximab , Campath I ) No prior antiBcell mAb conjugate radioisotope iodine I 131 ( e.g. , iodine I monoclonal antibody antiB1 ) yttrium Y No concurrent mAb therapy 12 month study No biologic therapy ( e.g. , monoclonal antibody , interferon alfa ) 12 month study No concurrent hematopoietic growth factor filgrastim ( GCSF ) Chemotherapy : See Disease Characteristics No chemotherapy within 5 day prior PBSC collection No concurrent chemotherapy 12 month study Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No concurrent radiotherapy 12 month study Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>